Contrarian Reads

DARPA Is Bad, HARPA Will Be Worse

A “new” proposal by the Biden administration to create a health-focused federal agency modeled after DARPA is not what it appears to be. Promoted as a way to “end cancer,” this resuscitated “health DARPA” conceals a dangerous agenda.       

India KOs The Delta Boogeyman

The prevailing narrative from Fauci, Walensky, and company is that Delta is more serious than anything before, and even though vaccines are even less effective against it, its spread proves the need to vaccinate even more people. Unless we do that, we must return to the very effective lockdowns and masks. In reality, India’s experience …

India KOs The Delta Boogeyman Read More »

The Delta Panic: Infected Or Injected?

Which makes me wonder how many people in the wave of the new “infections” test positive because they’ve been injected, not because they’ve been infected. Though the difference may not be easy to detect, other than the first group never getting sick, but then again, 80% of people have natural immunity against Covid to begin …

The Delta Panic: Infected Or Injected? Read More »

Rents—-To The Moon!

After dipping last spring, rents around the U.S. have not only recovered but are now blasting past their pre-pandemic levels. In 44 of the nation’s 50 largest metro areas, rents have surpassed where they were before the health crisis, according to data from Nationwide, the median rent reached a record high of $1,575 in …

Rents—-To The Moon! Read More »

The Weaponization Of January 6th

The major protest on January 6 in Washington D.C. was the culmination of weeks of rallies across the country. Although estimates vary widely, the January 6 rally featuring President Trump, attracted at least 500,000 supporters. The overwhelming majority of the participants heeded President Trump’s plea to “peacefully and patriotically make your voices heard.” Some participants …

The Weaponization Of January 6th Read More »

Crony Capitalism Alert: Here Comes Pfizer’s Massive Raid On Medicare

A federal judge will soon determine whether Pfizer can pay Medicare patients’ out-of-pocket expenses for one of its heart medications that is priced at $225,000 per year.